FREMONT, Calif., Nov. 6, 2019 /PRNewswire/ -- Ardelyx, Inc.
(Nasdaq: ARDX), a specialized biopharmaceutical company focused on
developing first-in-class medicines to improve treatment for people
with cardiorenal diseases, today announced a late-breaking oral
presentation of its recently announced AMPLIFY Phase 3 clinical
data will be presented at Kidney Week 2019, the American Society of
Nephrology's Annual Meeting, to be held November 5-10, 2019, in Washington D.C.
The late-breaking presentation will include data from AMPLIFY,
the pivotal Phase 3 study of tenapanor in combination with
phosphate binders in patients with chronic kidney disease (CKD) on
dialysis whose hyperphosphatemia was not previously controlled with
binders alone.
Details for the presentation are as follows:
Late-Breaking Oral
Presentation:
Title: Efficacy of tenapanor in
combination with phosphate binders in patients with CKD on dialysis
with uncontrolled hyperphosphatemia on phosphate binders alone.
Abstract Number: TH-PO1187
Date / Time: Thursday, November 7, 10:00am-12:00pm ET
Presenters: Pablo E. Pergola, Renal Associates, P.A.,
San Antonio, TX, USA, David P. Rosenbaum, Ardelyx, Inc., Fremont, CA, USA, Yang
Yang, Ardelyx, Inc., Fremont,
CA, USA, and Glenn Chertow,
Division of Nephrology, Stanford
University School of Medicine, Stanford, CA, USA
For more information about Kidney Week 2019,
visit https://www.asn-online.org/education/kidneyweek/.
About Ardelyx, Inc.
Ardelyx is focused on enhancing
the way people with cardiorenal diseases are treated by developing
first-in-class medicines. Ardelyx's cardiorenal pipeline includes
the Phase 3 development of tenapanor for the treatment of
hyperphosphatemia in people with end-stage renal disease (ESRD) who
are on dialysis, and RDX013, a potassium secretagogue program for
the potential treatment of high potassium, or hyperkalemia, a
problem among certain patients with kidney and/or heart disease. In
addition, Ardelyx has received approval of IBSRELA (tenapanor). To
efficiently bring its treatments to market, Ardelyx is pursuing
strategic collaborations for tenapanor for IBS-C and
hyperphosphatemia in certain territories. Ardelyx has established
agreements with Kyowa Kirin (formerly known as Kyowa Hakko Kirin)
in Japan, Fosun Pharma in
China and Knight Therapeutics in
Canada. For more information,
please visit http://www.ardelyx.com and connect with us on Twitter
@Ardelyx.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/ardelyx-announces-presentation-at-kidney-week-2019-300953193.html
SOURCE Ardelyx